Report Highlights
The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.
Report Includes
- An overview of the global market for bioengineered protein drugs.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
- A look at current technologies underlying the market as well as the effects new technologies will have on the market.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
- Profiles of the major companies involved in the production and modification of protein drugs.
Report Scope
The scope of this study involves the bioengineered protein therapeutics used in the pharmaceutical and the biopharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technologies involved, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments. The emerging markets cover countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.
The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes, peptide hormones and blood factors. These products are bioengineered and are produced by recombinant DNA technology. The only blood products considered in this report are recombinant blood products which are derived through the recombinant DNA technology process.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Related Reports
Pulmonary Drug Delivery Systems: Technologies and Global Markets
The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.
DNA Sequencing: Emerging Technologies and Applications
The global market for sequencing products and services reached $3.5 billion in 2012. This market is expected to grow to nearly $4.5 billion in 2013 and nearly 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.
Global Markets for Generic Drugs
The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.
Cancer Profiling and Pathways: Technologies and Global Markets
The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Chromatography in Pharmaceuticals and Biotechnology: Global Markets
The global market for chromatography in pharmaceuticals and biotechnology is estimated to grow from $13.3 billion in 2025 to reach $19.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.4% from 2025 to 2030.
Genome Editing: Technologies and Global Markets
The global market for genome editing is expected to grow from $10.8 billion in 2025 and is projected to reach $23.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.9% during the forecast period of 2025 to 2030.
Global Assisted Reproductive Technologies Market
The report provides an analysis of the global assisted reproductive technologies market and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented into procedure, product, end user, and region. The report focuses on the significant trends, challenges and technological advancements that alter the market and vendor landscape.
Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market
The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.
Global DNA Forensics Market
The global market for DNA forensics is projected to grow from an estimated $3.3 billion in 2025 to $4.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.
Report Highlights
-
The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
-
Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
-
Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.
Report Highlights
-
In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
-
Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
-
Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
-
Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
-
These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More